Oral amrinone in refractory congestive heart failure

Area of Science:

• Cardiology
• Pharmacology

Background:

• Advanced heart failure often persists despite standard treatments.
• New cardiotonic agents are needed to improve patient outcomes.

Purpose of the Study:

• To assess the acute, noninvasive effects of oral amrinone in patients with advanced heart failure.
• To evaluate the efficacy and safety of amrinone as a treatment for heart failure.

Main Methods:

• Nine patients with advanced heart failure received a single oral dose of amrinone.
• Left ventricular ejection fraction was measured using radionuclide ventriculography.
• Hemodynamic parameters and clinical signs were monitored.

Main Results:

• A significant improvement in left ventricular ejection fraction was observed (20.3% to 30.8%, p < 0.005).
• Effects were noted within 1 hour, peaking at 1-3 hours and lasting 4-6 hours.
• No significant changes in blood pressure, heart rate, or rhythm were recorded; no myocardial ischemia was evident.

Conclusions:

• Oral amrinone demonstrates acute efficacy in improving cardiac function in advanced heart failure.
• While promising, the chronic safety of oral amrinone needs further evaluation due to reported side effects.